Recent advances in cancer immunotherapy

Individual cancer specificity, high level of effectiveness for hematopoietic malignancies and modest side-effects have elevated immune approaches to first-line treatment of many cancers. Monoclonal anti-tumor cytotoxic antibodies, chemotherapeutic agents bound to anti-tumor antibodies, antibodies that suppress immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR)-T cells are established useful elements of cancer immunotherapy. It has recently been shown that patients receiving healthy donor encapsulated fecal microbiota before ICI therapy have better responses and fewer severe side-effects. Newly designed constructs of CAR-T or -NK cells with a different second CAR, a capacity to evoke production of suppressive antibodies to ICIs or to induce IL-12 or IL-15 generation are recent major advances especially valuable for immunotherapy of solid tumors. Gene-edited B cell/plasma cell clones that produce tumor cell cytotoxic antibodies in vivo and vaccination with tumor-specific neoantigens or mRNAs encoding tumor-specific neoantigens in combination with suppressive antibodies to ICIs are also meaningful recent advances.